Rafael Amado, Adaptimmune
Adaptimmune R&D chief Amado hits the exit amid a top-level shakeup as new CEO tries to revive ebbing enthusiasm
Adrian Rawcliffe doesn’t have any time to waste in making over the top team at Adaptimmune $ADAP, a high profile TCR-focused biotech that was once …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
